Bloch Stephen M sold $6.3M of LQDA (indirect holdings)

Bloch Stephen M sold 78,596 indirectly-held shares of Liquidia Corp (LQDA) at an average of $79.97 ($79.55–$80.66, $6.29M total) across 3 trades over 2026-07-20 to 2026-07-21.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jul 22, 2026, 11:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The only new information is the disclosed sale details (shares, price range, total value, post-transaction holdings).

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide a new fundamental catalyst.

03

What to watch

The article notes no 10b5-1 plan, but it does not provide the director’s broader holdings, tax/liquidity needs, or whether other insiders made offsetting purchases.

Relevance 6/10Novelty 3/10Timing: new SEC Form 4 filed 2026-07-22 for sales executed 2026-07-20 to 2026-07-21

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Liquidia Corp.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia director Stephen M. Bloch sold 78,596 shares in open-market trades for about $6.29M, per a new SEC Form 4 filing.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than based on new company performance data.

Evidence & confidence

The filing discloses transaction size, dates, and price range, but provides no new operational, regulatory, or financial catalyst for Liquidia.

Market effects

Minimal; insider sale in a single biotech does not imply sector-wide changes.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity events and may not reflect bearish expectations, especially without any accompanying negative company news.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure (LQDA).

  • Bloch Stephen M

    Director who sold shares via open-market transactions; indirect holdings reported.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.